126 related articles for article (PubMed ID: 21764132)
1. Synergistic targeting of leukemia with leukotoxin and chemotherapy.
Kreitman RJ
Leuk Res; 2011 Nov; 35(11):1438-9. PubMed ID: 21764132
[No Abstract] [Full Text] [Related]
2. In vitro synergism between LFA-1 targeting leukotoxin (Leukothera™) and standard chemotherapeutic agents in leukemia cells.
Gupta A; Le A; Belinka BA; Kachlany SC
Leuk Res; 2011 Nov; 35(11):1498-505. PubMed ID: 21664691
[TBL] [Abstract][Full Text] [Related]
3. Immunosuppressive properties of Actinobacillus actinomycetemcomitans leukotoxin.
Rabie G; Lally ET; Shenker BJ
Infect Immun; 1988 Jan; 56(1):122-7. PubMed ID: 3335399
[TBL] [Abstract][Full Text] [Related]
4. Combination of tipifarnib and rapamycin synergistically inhibits the growth of leukemia cells and overcomes resistance to tipifarnib via alteration of cellular signaling pathways.
Nagai T; Ohmine K; Fujiwara S; Uesawa M; Sakurai C; Ozawa K
Leuk Res; 2010 Aug; 34(8):1057-63. PubMed ID: 20071026
[TBL] [Abstract][Full Text] [Related]
5. Pretreatment of leukemic cells with low-dose decitabine markedly enhances the cytotoxicity of gemtuzumab ozogamicin.
Kurimoto M; Matsuoka H; Hanaoka N; Uneda S; Murayama T; Sonoki T; Nakakuma H
Leukemia; 2013 Jan; 27(1):233-5. PubMed ID: 22814292
[No Abstract] [Full Text] [Related]
6. LFA-1-targeting Leukotoxin (LtxA; Leukothera®) causes lymphoma tumor regression in a humanized mouse model and requires caspase-8 and Fas to kill malignant lymphocytes.
DiFranco KM; Johnson-Farley N; Bertino JR; Elson D; Vega BA; Belinka BA; Kachlany SC
Leuk Res; 2015 Jun; 39(6):649-56. PubMed ID: 25850729
[TBL] [Abstract][Full Text] [Related]
7. Leukotoxin (Leukothera®) targets active leukocyte function antigen-1 (LFA-1) protein and triggers a lysosomal mediated cell death pathway.
DiFranco KM; Gupta A; Galusha LE; Perez J; Nguyen TK; Fineza CD; Kachlany SC
J Biol Chem; 2012 May; 287(21):17618-17627. PubMed ID: 22467872
[TBL] [Abstract][Full Text] [Related]
8. Ultrastructural characterization of apoptosis in bovine lymphocytes exposed to Pasteurella haemolytica leukotoxin.
Sun Y; Clinkenbeard KD; Ownby CL; Cudd L; Clarke CR; Highlander SK
Am J Vet Res; 2000 Jan; 61(1):51-6. PubMed ID: 10630778
[TBL] [Abstract][Full Text] [Related]
9. The combination of a histone deacetylase inhibitor with the Bcl-2 homology domain-3 mimetic GX15-070 has synergistic antileukemia activity by activating both apoptosis and autophagy.
Wei Y; Kadia T; Tong W; Zhang M; Jia Y; Yang H; Hu Y; Tambaro FP; Viallet J; O'Brien S; Garcia-Manero G
Clin Cancer Res; 2010 Aug; 16(15):3923-32. PubMed ID: 20538760
[TBL] [Abstract][Full Text] [Related]
10. The histone deacetylase inhibitor MS-275 interacts synergistically with fludarabine to induce apoptosis in human leukemia cells.
Maggio SC; Rosato RR; Kramer LB; Dai Y; Rahmani M; Paik DS; Czarnik AC; Payne SG; Spiegel S; Grant S
Cancer Res; 2004 Apr; 64(7):2590-600. PubMed ID: 15059916
[TBL] [Abstract][Full Text] [Related]
11. Effect of combined deferasirox and 5-azacytidine treatment on human leukemia cells in vitro.
Imanishi S; Takahashi R; Ohsuga M; Ohyashiki K; Ohyashiki JH
Ann Hematol; 2015 Sep; 94(9):1601-2. PubMed ID: 26044890
[No Abstract] [Full Text] [Related]
12. Effect of histone deacetylase inhibitors trichostatin A and valproic acid on etoposide-induced apoptosis in leukemia cells.
Jasek E; Lis GJ; Jasinska M; Jurkowska H; Litwin JA
Anticancer Res; 2012 Jul; 32(7):2791-9. PubMed ID: 22753739
[TBL] [Abstract][Full Text] [Related]
13. LukS-PV induces mitochondrial-mediated apoptosis and G0/G1 cell cycle arrest in human acute myeloid leukemia THP-1 cells.
Bu S; Xie Q; Chang W; Huo X; Chen F; Ma X
Int J Biochem Cell Biol; 2013 Aug; 45(8):1531-7. PubMed ID: 23702031
[TBL] [Abstract][Full Text] [Related]
14. Combined treatment of 3-hydroxyflavone and imatinib mesylate increases apoptotic cell death of imatinib mesylate-resistant leukemia cells.
Kim JH; Song M; Kang GH; Lee ER; Choi HY; Lee C; Kim JH; Kim Y; Koo BN; Cho SG
Leuk Res; 2012 Sep; 36(9):1157-64. PubMed ID: 22770910
[TBL] [Abstract][Full Text] [Related]
15. Reversal of cytosine arabinoside (ara-C) resistance by the synergistic combination of 6-thioguanine plus ara-C plus PEG-asparaginase (TGAP) in human leukemia lines lacking or expressing p53 protein.
Fu CH; Martin-Aragon S; Weinberg KI; Ardi VC; Danenberg PV; Avramis VI
Cancer Chemother Pharmacol; 2001 Aug; 48(2):123-33. PubMed ID: 11561778
[TBL] [Abstract][Full Text] [Related]
16. Is LukS-PV a novel experimental therapy for leukemia?
Shan W; Ma X; Deng F
Gene; 2017 Feb; 600():44-47. PubMed ID: 27916717
[TBL] [Abstract][Full Text] [Related]
17. Test this patient's leukemic stem cells in a non-clonogenic chemosensitivity assay, treat according to standard protocols.
Hofmann V; Berens ME
Eur J Cancer Clin Oncol; 1984 Sep; 20(9):1119-21. PubMed ID: 6541132
[No Abstract] [Full Text] [Related]
18. The multikinase inhibitor sorafenib potentiates TRAIL lethality in human leukemia cells in association with Mcl-1 and cFLIPL down-regulation.
Rosato RR; Almenara JA; Coe S; Grant S
Cancer Res; 2007 Oct; 67(19):9490-500. PubMed ID: 17909059
[TBL] [Abstract][Full Text] [Related]
19. Pharmacological inhibitors of the mitogen-activated protein kinase (MAPK) kinase/MAPK cascade interact synergistically with UCN-01 to induce mitochondrial dysfunction and apoptosis in human leukemia cells.
Dai Y; Yu C; Singh V; Tang L; Wang Z; McInistry R; Dent P; Grant S
Cancer Res; 2001 Jul; 61(13):5106-15. PubMed ID: 11431348
[TBL] [Abstract][Full Text] [Related]
20. The in-vitro antiproliferative effect of PRI-2191 and imatinib applied in combined treatment with cisplatin, idarubicin, or docetaxel on human leukemia cells.
Switalska M; Nasulewicz-Goldeman A; Opolska A; Maciejewska M; Kutner A; Wietrzyk J
Anticancer Drugs; 2012 Jan; 23(1):70-80. PubMed ID: 21934605
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
